Stock Track | Alumis Inc. Soars 5.67% in Pre-Market on Positive Trial Results and Analyst Upgrades

Stock Track

Jan 07

Alumis Inc. (ALMS) saw its stock rise 5.67% in pre-market trading on Wednesday, following a surge of 95.31% in the previous session. The rally was driven by positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib for moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints with high statistical significance.

Additionally, the stock received multiple analyst upgrades, with Leerink Partners raising its target price to $32 from $20, Morgan Stanley increasing it to $33 from $22, and Wells Fargo lifting it to $39 from $17. These upgrades reflect growing confidence in Alumis Inc.'s prospects following the successful trial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1142692175"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142692175\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142692175?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142692175","market":"nz","top_or_hot":-1,"title":"Stock Track | Alumis Inc. Soars 5.67% in Pre-Market on Positive Trial Results and Analyst Upgrades","media":"Stock Track","content":"<p>Alumis Inc. (ALMS) saw its stock rise 5.67% in pre-market trading on Wednesday, following a surge of 95.31% in the previous session. The rally was driven by positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib for moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints with high statistical significance.</p><p>Additionally, the stock received multiple analyst upgrades, with Leerink Partners raising its target price to $32 from $20, Morgan Stanley increasing it to $33 from $22, and Wells Fargo lifting it to $39 from $17. These upgrades reflect growing confidence in Alumis Inc.'s prospects following the successful trial results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alumis Inc. Soars 5.67% in Pre-Market on Positive Trial Results and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alumis Inc. Soars 5.67% in Pre-Market on Positive Trial Results and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-07 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alumis Inc. (ALMS) saw its stock rise 5.67% in pre-market trading on Wednesday, following a surge of 95.31% in the previous session. The rally was driven by positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib for moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints with high statistical significance.</p><p>Additionally, the stock received multiple analyst upgrades, with Leerink Partners raising its target price to $32 from $20, Morgan Stanley increasing it to $33 from $22, and Wells Fargo lifting it to $39 from $17. These upgrades reflect growing confidence in Alumis Inc.'s prospects following the successful trial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALMS","symbol_name":"Alumis Inc.","start_time":0,"source_url":"","article_id":"1142692175","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142692175","pubTimestamp":1767787707,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alumis Inc. (ALMS) saw its stock rise 5.67% in pre-market trading on Wednesday, following a surge of 95.31% in the previous session. The rally was driven by positive topline results from its Phase 3...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALMS":"Alumis Inc."},"translate_title":"个股追踪|Alumis Inc.盘前飙升5.67%，因试验结果积极和分析师上调评级","themeId":"9677d5b602107425b8711c4b21a742bf","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1},"content_text":"Alumis Inc. (ALMS) saw its stock rise 5.67% in pre-market trading on Wednesday, following a surge of 95.31% in the previous session. The rally was driven by positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib for moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints with high statistical significance.Additionally, the stock received multiple analyst upgrades, with Leerink Partners raising its target price to $32 from $20, Morgan Stanley increasing it to $33 from $22, and Wells Fargo lifting it to $39 from $17. These upgrades reflect growing confidence in Alumis Inc.'s prospects following the successful trial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}